Effect of Lecithin-based Curcuma and Boswellia on Post-acute COVID-19 IBS
CompletedNot applicableNCT06423586
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This open-label study investigates the effects of lecithin-based formulations of Curcuma longa (Meriva™) and Boswellia serrata (Casperome™) extracts on post-acute COVID-19 irritable bowel syndrome (PCIBS) and irritable bowel syndrome (IBS) without prior COVID-19 infection. A total of 44 participants, 16 with PCIBS and 28 controls with IBS, were supplemented for 30 days. Outcomes measured included abdominal bloating, abdominal pain, enteral dysbiosis, and global assessment of efficacy. The study found significant reductions in bloating and pain in both groups, with a notable decrease in dysbiosis only in the IBS group. This suggests potential benefits of the supplementation in managing gastrointestinal symptoms associated with PCIBS and IBS.
Study details
- Official title
- Positive Effect of Lecithin-based Delivery Form of Curcuma and Boswellia Extracts on Post-acute COVID-19 Irritable Bowel Syndrome. Two Cohorts of an Open-label Study.
- Conditions
- Post-Acute COVID-19 Syndrome
- Irritable Bowel Syndrome
- Abdominal Pain
- Dysbiosis
- Interventions
- Dietary supplement: Curcuma longa and Boswellia serrata extracts
- Sponsor
- Azienda di Servizi alla Persona di Pavia
- Start date
- 2021-09-01
- Primary completion
- 2021-10-01
- Sex
- All
- Age range
- from 18 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Countries
- Italy
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Age: 18-75 years, male or female. * Diagnosis of post-acute COVID-19 irritable bowel syndrome (PCIBS) 60-120 days after the end of infection. * Diagnosis of irritable bowel syndrome (IBS) without prior COVID-19 infection. * Evidence of functional abdominal bloating/distention (FAB/D) type of IBS according to Mearin et al. * Presence of enteral dysbiosis defined by increased urinary indican values with normal skatole urinary concentration. Exclusion Criteria: * Normal urinary indican values or increased urinary skatole values. * Subjects already on a low FODMAP diet or other dietary restrictions such as gluten-free diet or lactose-free diet within the past 6 months. * Allergies to soy, nuts, or seafood, or insulin-dependent diabetes. * Known history of celiac disease, symptomatic diverticular disease, inflammatory bowel disease, or microscopic colitis. * Prior small bowel or colonic surgery or cholecystectomy. * Presence of bloody diarrhea or severe vomiting. * Severe renal disease (serum creatinine \>1.5 mg/dL) or liver disease (altered liver function tests).
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06423586